Polar Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Polar Capital’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-769,425	Closed	-$10.8M	–	308
2020 Q1	$10.8M	Buy	+769,425	New	+$12.6M	0.12%	164

Other funds holding MIRM

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Polar Capital's MIRM Position: Q2 2020 in Review

Polar Capital sold out of Mirum Pharmaceuticals (MIRM) in Q2 2020, closing a stake of 769,425 shares — an estimated $10.8M sold.

Polar Capital first reported a position in MIRM in Q1 2020 and held it in 1 quarter. The position peaked at $10.8M in Q1 2020. 58 funds tracked by Wall St. Rank hold MIRM as of Q2 2020.

Polar Capital reported no remaining Mirum Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Polar Capital sold 769,425 Mirum Pharmaceuticals shares in Q2 2020, an estimated $10.8M.
Polar Capital first reported a position in Mirum Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Polar Capital's Mirum Pharmaceuticals position peaked at $10.8M in Q1 2020.
58 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2020.

Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.